Diebold Nixdorf, Incorporated (DBD) is a publicly traded Technology sector company. As of October 5, 2026, DBD trades at $65.53 with a market cap of $2.16B and a P/E ratio of 21.33. DBD moved +2.92% today. Year to date, DBD is -3.33%; over the trailing twelve months it is +12.75%. Its 52-week range spans $34.88 to $92.09. Analyst consensus is buy with an average price target of $100.00. Rallies surfaces DBD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
US court warns more Jackson Walker cases could be tainted by relationship with judge: A Houston bankruptcy judge ordered Jackson Walker to explain why it should not be sanctioned for failing to disclose its work on Diebold Nixdorf’s 2023 bankruptcy. The judge ordered the firm to list by October 15 all cases in which it appeared before former judge David Jones.
| Metric | Value |
|---|---|
| Price | $65.53 |
| Market Cap | $2.16B |
| P/E Ratio | 21.33 |
| EPS | $3.08 |
| Dividend Yield | 0.00% |
| 52-Week High | $92.09 |
| 52-Week Low | $34.88 |
| Volume | 250.21K |
| Avg Volume | 0 |
| Revenue (TTM) | $3.87B |
| Net Income | $113.90M |
| Gross Margin | 25.25% |
2 analysts cover DBD: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $100.00.